These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31141116)

  • 41. [Treatment of generalized (progressive) scleroderma].
    Balda BR
    Dtsch Med Wochenschr; 1972 Dec; 97(48):1876-8. PubMed ID: 4117979
    [No Abstract]   [Full Text] [Related]  

  • 42. Anesthetic Management of a Patient With Systemic Sclerosis and Microstomia.
    Shionoya Y; Kamiga H; Tsujimoto G; Nakamura E; Nakamura K; Sunada K
    Anesth Prog; 2020; 67(1):28-34. PubMed ID: 32191504
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of hyaluronidase by iontophoresis in the treatment of generalized scleroderma.
    POPKIN RJ
    J Invest Dermatol; 1951 Feb; 16(2):97-102. PubMed ID: 14814336
    [No Abstract]   [Full Text] [Related]  

  • 44. Impact of systemic sclerosis oral manifestations on patients' health-related quality of life: A systematic review.
    Smirani R; Truchetet ME; Poursac N; Naveau A; Schaeverbeke T; Devillard R
    J Oral Pathol Med; 2018 Oct; 47(9):808-815. PubMed ID: 29855076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A neoteric multidrug combination: novel approach to limited cutaneous systemic scleroderma involving the face.
    Kumar MH; Kumar MS; Kumar SH; Kumar KS
    BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 27033280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Oral manifestations of systemic sclerosis].
    Salem B; Rim BH; Sihem BK; Maher B
    Pan Afr Med J; 2013; 16():114. PubMed ID: 24778751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of hyaluronidase in scleroderma.
    CLAESSON U; LINDQUIST B
    Acta Paediatr (Stockh); 1953 May; 42(3):278-81. PubMed ID: 13079763
    [No Abstract]   [Full Text] [Related]  

  • 48. Aberrant serum hyaluronan and hyaluronidase levels in scleroderma.
    Neudecker BA; Stern R; Connolly MK
    Br J Dermatol; 2004 Mar; 150(3):469-76. PubMed ID: 15030329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Osseointegrated implants for prosthetic reconstruction in a patient with scleroderma: report of a case.
    Jensen J; Sindet-Pedersen S
    J Oral Maxillofac Surg; 1990 Jul; 48(7):739-41. PubMed ID: 2358953
    [No Abstract]   [Full Text] [Related]  

  • 50. [Histomorphologic and histochemical changes in the skin during the treatment of scleroderma].
    Sych LI; Trofimova LIa
    Vestn Dermatol Venerol; 1971; 45(3):22-6. PubMed ID: 5122538
    [No Abstract]   [Full Text] [Related]  

  • 51. [Progressive systemic sclerosis with polydontia. Report of an unusual case].
    Seoane Leston JM; Sanz Asenjo A; Romero Mendez MA; Esparza Gomez GA; Cerero Lapiedra R
    Rev Eur Odontoestomatol; 1989; 1(2):97-100. PubMed ID: 2638834
    [No Abstract]   [Full Text] [Related]  

  • 52. The use of hyaluronidase in the treatment of chronic skin ulcers in diffuse generalized scleroderma.
    POPKIN RJ
    Angiology; 1952 Aug; 3(4):335-42. PubMed ID: 14952881
    [No Abstract]   [Full Text] [Related]  

  • 53. [Treatment of scleroderma with depolymerizing agents].
    Konopík J; Krs V
    Cas Lek Cesk; 1982 Nov; 121(44):1368-72. PubMed ID: 7172189
    [No Abstract]   [Full Text] [Related]  

  • 54. Ivabradine in systemic sclerosis related pulmonary arterial hypertension.
    Correale M; Montrone D; Ieva R; Di Biase M; Brunetti ND
    Eur J Intern Med; 2012 Dec; 23(8):e210-1. PubMed ID: 23021874
    [No Abstract]   [Full Text] [Related]  

  • 55. Scleroderma: oral manifestations and treatment challenges.
    Fischer DJ; Patton LL
    Spec Care Dentist; 2000; 20(6):240-4. PubMed ID: 18481415
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discussion of the Article "Effects of Fat Grafting Containing Stem Cells in Microstomia and Microcheilia Derived from Systemic Sclerosis" by Dr. Blezien and Colleagues.
    Guyuron B
    Aesthetic Plast Surg; 2020 Feb; 44(1):239. PubMed ID: 28842724
    [No Abstract]   [Full Text] [Related]  

  • 57. Pitting oedema in early diffuse systemic scleroderma.
    Englert H; Low S
    Ann Rheum Dis; 2001 Nov; 60(11):1079-80. PubMed ID: 11688491
    [No Abstract]   [Full Text] [Related]  

  • 58. [On the mechanism of action of lidase in the therapy of patients with scleroderma].
    RAKHMANOV VA; KHMEL'NITSKII RKh
    Vestn Dermatol Venerol; 1959; 33():3-7. PubMed ID: 14435955
    [No Abstract]   [Full Text] [Related]  

  • 59. Successful treatment of microstomia with UVA1 phototherapy in systemic sclerosis.
    Tewari A; Garibaldinos T; Lai-Cheong J; Groves R; Sarkany R; Branislav Novakovic L
    Photodermatol Photoimmunol Photomed; 2011 Apr; 27(2):113-4. PubMed ID: 21392116
    [No Abstract]   [Full Text] [Related]  

  • 60. [Observations of the course of scleroderma after combined Hylase-carnitine therapy].
    Nitzschner H
    Z Arztl Fortbild (Jena); 1975 Nov; 69(21):1108. PubMed ID: 1226844
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.